This Article Full Text Full Text (PDF) All Versions of this Article: 200504-531OEv1 172/5/523    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Spiro, S. G. Articles by Silvestri, G. A. Search for Related Content PubMed PubMed Citation Articles by Spiro, S. G. Articles by Silvestri, G. A.

One Hundred Years of Lung Cancer

Department of Thoracic Medicine, Middlesex Hospital, London, United Kingdom; and Division of Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston, South Carolina

Correspondence and requests for reprints should be addressed to Stephen G. Spiro, M.D., F.R.C.P., Department of Thoracic Medicine, Middlesex Hospital, Mortimer Street, London WIT 3AA, UK. E-mail: stephen.spiro{at}uclh.org

ABSTRACT

A hundred years ago, lung cancer was a reportable disease, and it is now the commonest cause of death from cancer in both men and women in the developed world, and before long, will reach that level in the developing world as well. The disease has no particular symptoms or signs for its detection at an early stage. Most patients therefore present with advanced stage IIIB or IV disease. Screening tests began in the 1950s with annual chest x-ray films and sputum cytology but they resulted in no improvement in overall mortality compared with control subjects. The same question is now being asked of spiral low-dose computed tomographic scanning. There have been big refinements in the staging classification of lung cancer and advances in stage identification using minimally invasive technology. Postsurgical mortality has declined from the early days of the 1950s but 5-year cure rates have only barely improved. The addition of chemotherapy to radical radiotherapy, together with novel radiotherapy techniques, is gradually improving the outcome for locally advanced, inoperable non–small cell lung cancer. Chemotherapy offers modest survival improvement for patients with non–small cell lung cancer, the modern agents being better tolerated resulting in an improved quality of life. The management of small cell lung cancer, which appeared so promising at the beginning of the 1970s, has hit a plateau with very little advance in outcome over the last 15 years. The most important and cost-effective management for lung cancer is smoking cessation, but for those with the disease, novel agents and treatment approaches are urgently needed.

Key Words: lung cancer • one hundred years • staging • treatment

This article has been cited by other articles:

				B. P. van Putte, M. Grootenboers, W.-J. van Boven, J. M. H. Hendriks, P. E. Y. van Schil, G. Guetens, G. De Boeck, G. Pasterkamp, F. Schramel, and G. Folkerts Pharmacokinetics of Gemcitabine when Delivered by Selective Pulmonary Artery Perfusion for the Treatment of Lung Cancer Drug Metab. Dispos., April 1, 2008; 36(4): 676 - 681. [Abstract] [Full Text] [PDF]

				I. I. Na, B. H. Byun, H. J. Kang, G. J. Cheon, J. S. Koh, C. H. Kim, D. H. Choe, B.-Y. Ryoo, J. C. Lee, S. M. Lim, et al. 18F-Fluoro-2-Deoxy-Glucose Uptake Predicts Clinical Outcome in Patients with Gefitinib-Treated Non-Small Cell Lung Cancer Clin. Cancer Res., April 1, 2008; 14(7): 2036 - 2041. [Abstract] [Full Text] [PDF]

				G. Sharma, J. Freeman, D. Zhang, and J. S. Goodwin Trends in End-of-Life ICU Use Among Older Adults With Advanced Lung Cancer Chest, January 1, 2008; 133(1): 72 - 78. [Abstract] [Full Text] [PDF]

				C. Nahmias, W. T. Hanna, L. M. Wahl, M. J. Long, K. F. Hubner, and D. W. Townsend Time Course of Early Response to Chemotherapy in Non-Small Cell Lung Cancer Patients with 18F-FDG PET/CT J. Nucl. Med., May 1, 2007; 48(5): 744 - 751. [Abstract] [Full Text] [PDF]

				M. Kunnimalaiyaan and H. Chen Tumor Suppressor Role of Notch-1 Signaling in Neuroendocrine Tumors Oncologist, May 1, 2007; 12(5): 535 - 542. [Abstract] [Full Text] [PDF]

				J. K. Rho, Y. J. Choi, B.-Y. Ryoo, I. I. Na, S. H. Yang, C. H. Kim, and J. C. Lee p53 Enhances Gefitinib-Induced Growth Inhibition and Apoptosis by Regulation of Fas in Non-Small Cell Lung Cancer Cancer Res., February 1, 2007; 67(3): 1163 - 1169. [Abstract] [Full Text] [PDF]

				X.-c. Chen, R. Wang, X. Zhao, Y.-q. Wei, M. Hu, Y.-s. Wang, X.-w. Zhang, R. Zhang, L. Zhang, B. Yao, et al. Prophylaxis against carcinogenesis in three kinds of unestablished tumor models via IL12-gene-engineered MSCs Carcinogenesis, December 1, 2006; 27(12): 2434 - 2441. [Abstract] [Full Text] [PDF]

				C.-R. Chien and M.-S. Lai Trends in the pattern of care for lung cancer and their correlation with new clinical evidence: experiences in a university-affiliated medical center. American Journal of Medical Quality, November 1, 2006; 21(6): 408 - 414. [Abstract] [PDF]

				J. R. Jett and Y. E. Miller Update in lung cancer 2005. Am. J. Respir. Crit. Care Med., April 1, 2006; 173(7): 695 - 697. [Full Text] [PDF]

				T. Bunyaviroch and R. E. Coleman PET Evaluation of Lung Cancer J. Nucl. Med., March 1, 2006; 47(3): 451 - 469. [Full Text] [PDF]

				P H Jarritt, A R Hounsell, K J Carson, D Visvikis, V P Cosgrove, J C Clarke, D P Stewart, V A L Fleming, R L Eakin, and A Zatari Use of combined PET/CT images for radiotherapy planning: initial experiences in lung cancer Br. J. Radiol., November 1, 2005; Supplement_28(1): 33 - 40. [Abstract] [Full Text] [PDF]